Portola Pharmaceuticals Announces Enrollment Has Begun in Phase 1/2 Study of PRT2070, an Oral Dual Syk/JAK Inhibitor for Genetically-Defined Hematologic Cancers
October 24, 2013 16:00 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 24, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals (Nasdaq:PTLA) today announced that patient enrollment has begun in its PRT2070 Phase 1/2 proof-of-concept...
Portola Announces Pricing of Public Offering of Common Stock
October 17, 2013 08:32 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 17, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today the pricing of its underwritten public offering of 6,366,513 shares of its...
Portola Pharmaceuticals Announces Proposed Offering of Common Stock
October 16, 2013 06:56 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 16, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it has commenced an underwritten public offering of shares of its common...
Portola Pharmaceuticals Announces Release of Lock-up Restriction for Common Stock Held by a Director of the Company
October 15, 2013 17:05 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) announced today that Morgan Stanley & Co. LLC and Credit Suisse Securities (USA) LLC, the...
Portola Pharmaceuticals Announces First Phase 2 Results Demonstrating Extended Duration Infusion With Andexanet Alfa (PRT4445*) Provides Prolonged Reversal of Anticoagulation Activity of Factor Xa Inhibitor Eliquis(R)
October 14, 2013 17:05 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 14, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced new interim findings from a Phase 2 proof-of-concept study of its...
Portola Pharmaceuticals Announces Initiation of Phase 1/2 Clinical Study of PRT2070
October 09, 2013 08:00 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 9, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that it has initiated a Phase 1/2 clinical study of PRT2070, a novel, oral,...
Portola Pharmaceuticals Announces Participation at Upcoming Investor Conferences
September 05, 2013 08:00 ET
|
Portola Pharmaceuticals, Inc.
SOUTH SAN FRANCISCO, Calif., Sept. 5, 2013 (GLOBE NEWSWIRE) -- Portola Pharmaceuticals, Inc. (Nasdaq:PTLA) today announced that William Lis, chief executive officer, will present at the following...